Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) was the recipient of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 564,000 shares, a drop of 44.7% from the February 13th total of 1,020,000 shares. Approximately 2.9% of the company’s shares are short sold. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is currently 0.5 days.

Vigil Neuroscience Trading Down 4.3 %

NASDAQ:VIGL opened at $2.02 on Friday. The stock has a market capitalization of $82.58 million, a PE ratio of -0.98 and a beta of 1.82. Vigil Neuroscience has a 1-year low of $1.49 and a 1-year high of $6.06. The firm has a fifty day simple moving average of $2.34 and a 200 day simple moving average of $2.79.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). On average, equities analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

Institutional investors have recently bought and sold shares of the business. Walleye Capital LLC increased its holdings in shares of Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after acquiring an additional 92,217 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of Vigil Neuroscience in the third quarter valued at about $442,000. Point72 Asset Management L.P. lifted its stake in shares of Vigil Neuroscience by 7.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock worth $5,440,000 after buying an additional 115,000 shares during the last quarter. Geode Capital Management LLC grew its stake in Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after buying an additional 66,712 shares during the last quarter. Finally, abrdn plc raised its holdings in Vigil Neuroscience by 124.9% in the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after acquiring an additional 293,461 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on VIGL. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. William Blair assumed coverage on shares of Vigil Neuroscience in a report on Wednesday, December 4th. They issued an “outperform” rating on the stock. HC Wainwright dropped their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday. Wedbush decreased their target price on Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday. Finally, JMP Securities restated a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vigil Neuroscience presently has a consensus rating of “Buy” and an average price target of $16.25.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.